The purpose of this study is to compare the drug levels of darunavir obtained after
administration of a single administration of the 800 mg tablet (new formulation) to that
following administration of two 400 mg commercial tablets formulation when administered under
fed and fasted conditions to those also taking low-dose ritonavir. Darunavir is marketed for
the treatment of HIV. The short-term safety and tolerability of darunavir following
administration of a single 800 mg dose of darunavir given to healthy volunteers taking taking
low-dose ritonavir will also be assessed.